Typically, during human disease modeling and cell-based therapies, the capacity to reprogram somatic cells to induce iPSCs has provided great value. Nowadays, iPSC derivatives have already reached the stage of clinical testing in human patients. Using different techniques to produce induced iPSCs needs that scientists choose the suitable reprogramming method for generating iPSCs, thus the resulting iPSCs enable to be transitioned towards clinical applications effectively. Generally steps in a reprogramming experiment include tissue selection, proceeding through iPSC generation, possible transgene excision to produce iPSC cells that are ready for use in a translational setting. Check more details: chemical reprogramming of human somatic cells to pluripotent stem cells
